Regeneron to challenge Ipsen as FDA clears bone disease drug

The FDA has approved Regeneron's Pasatru for fibrodysplasia ossificans progressiva, setting up competition against Ipsen's existing bone disease treatment which has had poor sales.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 19 Aug 2026 and 31 Aug 2026.